Browse the evidence

SCD1 inhibitors have been developed to treat various types of cancer.

SCD1 inhibitors could be a promising avenue for cancer therapy.

Several biomarkers reflecting various pathophysiological pathways linking obesity and cardiometabolic diseases have been identified.

Practitioners should consider these biomarkers in understanding obesity-related health risks.

The evidence for a causal role of many classical obesity biomarkers in disease etiology remains limited.

Caution is advised when using classical biomarkers for disease prediction.

There is increasing interest in novel biomarkers for improved, personalized prevention of obesity-related diseases.

Practitioners should explore novel biomarkers for better prevention strategies.

There are existing knowledge gaps in the molecular adaptations to exercise that warrant continued research effort.

Researchers should focus on addressing these knowledge gaps to advance the field.

Higher plasma concentrations of TMAO are associated with a 30% increased risk of death from any cause among older adults.

Practitioners should consider monitoring TMAO levels in older adults as a potential risk factor for mortality.

Choline is associated with a 19% increased risk of death from any cause among older adults.

Monitoring choline levels may also be relevant for assessing mortality risk in older adults.

Carnitine and butyrobetaine are each associated with a 26% increased risk of death from any cause among older adults.

Practitioners should be aware of the potential risks associated with elevated levels of carnitine and butyrobetaine in older adults.

Identifying components of neuroendocrine systems is important for developing obesity therapies.

Research should focus on neuroendocrine components to inform obesity treatment strategies.

Reduced microbial diversity in the gut is implicated in several gastrointestinal diseases and cancers.

Maintaining gut microbiome diversity may be crucial for preventing gastrointestinal diseases.

Tirzepatide does not seem to have a classical co-activating mode of action in humans.

Understanding the unique action of tirzepatide may inform treatment strategies for type 2 diabetes.

Inhibition of miR-155 expression in macrophages improves EPC viability and reduces inflammation.

Targeting miR-155 may be a therapeutic strategy to enhance endothelial repair in obesity.

Semaglutide attenuated cardiac inflammation through restoring RKIP expression and inhibiting the TBK1-NF-κB pathway.

Understanding this mechanism can help in developing targeted therapies for cardiac inflammation in diabetes.

Semaglutide's anti-inflammatory effect is mediated through the Sirt3-dependent RKIP pathway, rather than glucose lowering.

This suggests that semaglutide may have benefits beyond just lowering blood sugar in diabetic patients.

Fatty acids increase GDF15 levels dose dependently, with the greatest response observed with linolenic acid.

Incorporating fatty acids like linolenic acid may enhance GDF15 levels, potentially influencing dietary responses.

There is a significant difference in the profile of reporting risk and time-to-onset of GADRs between semaglutide and liraglutide.

Understanding these differences can help tailor obesity treatment to individual patient needs.

Multiple hallmarks of ageing have been identified that are fundamental across taxa.

Understanding these hallmarks can guide research and interventions in age-related diseases.

Ingestion of deuterated water results in 2 H enrichment of the body water pool, which is incorporated into tissue proteins.

This highlights a novel approach to studying protein synthesis in muscle tissue.

Ex-DARPin fusion proteins have a comparable half-life of 29-32 hours, which is much longer than that of native Ex (0.5 hours in rats).

Longer half-life of Ex-DARPin fusion proteins may reduce the frequency of administration needed for effective treatment.

Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.

Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.

Mendelian randomisation did not find evidence that genetically proxied GLP-1RA increased suicide attempts in a general population cohort.

There is no genetic evidence to support an association between GLP-1RA and increased suicide attempts, suggesting safety in this regard.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.

This formulation may provide a long-lasting treatment option for diabetes management.